MYC and ovarian cancer: The compound 2-[(8-bromo-5-methyl-5 H-[1,2,4]triazino[5,6-b]indol-3-yl)thio]-N-(1-phenylethyl)acetamide (C20H18BrN5OS, ChemBridge ID: 6896009) has been regarded as a lead IGF2BP1 inhibitor to obstruct the binding of IGF2BP1 to MYC mRNA and can obviously restrain IGF2BP1-containing ovarian cancer cell proliferation [117].